PRPO (Precipio) רווח נקי למניה (EPS TTM)

Precipio, Inc. (PRPO) generates revenue through the sale of reagents and expert blood analyses for oncology centers. The company's average annual revenue per unit confirms the profit trend, with the value stabilizing at -0.68. Stability is ensured by a staff of elite pathologists protected from burnout. However, pricing power is limited by insurance caps, despite the possession of ICE-Cold PCR patents.

Net income per share over 12 months measures the actual return on each unit of capital, smoothing out short-term volatility. This metric assesses the business's ability to generate profit after all deductions. By analyzing the 12-month net income per share trend, an investor can see the effectiveness of ESG standard implementation and waste optimization in Precipio, Inc. (PRPO) diagnostics. Resource savings directly impact the bottom line, confirming the company's operational viability.